{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T14:41:03Z","timestamp":1688481663682},"reference-count":20,"publisher":"American Society of Consultant Pharmacists","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>This case illustrates the pharmacist\u2019s role in the outpatient management of heart failure with reduced ejection fracture in a community-dwelling older person. In this case, the patient has a long-standing history of heart failure because of ischemic causes. Relatively active and\n working full-time, he presented to the pharmacist clinic for optimization of heart failure therapy. This case focuses on the role of mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 inhibitors in heart failure with reduced ejection fraction management.<\/jats:p>","DOI":"10.4140\/tcp.n.2023.288","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T08:47:56Z","timestamp":1688028476000},"page":"288-294","source":"Crossref","is-referenced-by-count":0,"title":["Geriatric Pharmacotherapy Case Series: Heart Failure With Reduced Ejection Fraction Pharmacotherapy Optimization in Older People"],"prefix":"10.4140","volume":"38","author":[{"given":"Elizabeth K.","family":"Pogge","sequence":"first","affiliation":[{"name":"Midwestern University College of Pharmacy, Glendale, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marrisa","family":"Trevino","sequence":"additional","affiliation":[{"name":"Midwestern University College of Pharmacy, Glendale, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Midwestern University College of Pharmacy, Glendale, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","article-title":"Polypharmacy definition and prevalence in heart failure: a systematic review.","volume":"27","year":"2022","journal-title":"Heart Fail Rev."},{"key":"ref2","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"145","year":"2022","journal-title":"Circulation."},{"issue":"8","key":"ref3","first-page":"e254","article-title":"Heart disease and stroke statistics\u20142021 update: a report from the American Heart Association.","volume":"143","year":"2021","journal-title":"Circulation."},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy in heart failure with reduced ejection fraction: the CHAMP-HF Registry.","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcomes for patients with heart failure.","volume":"5","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction.","volume":"8","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref7","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association.","year":"2018","journal-title":"Hypertension."},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"e12459","DOI":"10.1111\/1755-5922.12459","article-title":"Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.","volume":"36","year":"2018","journal-title":"Cardiovasc Ther."},{"issue":"6","key":"ref9","first-page":"772","article-title":"update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee.","volume":"77","year":"2021","journal-title":"J Am Coll Cardiol."},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.","volume":"61","year":"2018","journal-title":"Diabetologia."},{"issue":"21","key":"ref11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","year":"2019","journal-title":"N Engl J Med."},{"issue":"15","key":"ref12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","year":"2020","journal-title":"N Engl J Med."},{"issue":"16","key":"ref13","first-page":"1451","article-title":"Empagliflozin in heart failure with preserved ejection fraction.","volume":"383","year":"2021","journal-title":"N Engl J Med."},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","year":"2022","journal-title":"N Engl J Med."},{"key":"ref15","year":"2022","journal-title":"Jardiance (empagliflozin) [package insert]."},{"key":"ref16","year":"2021"},{"issue":"15","key":"ref17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","year":"2020","journal-title":"N Engl J Med."},{"key":"ref18","first-page":"S45","article-title":"Safety of sodium glucose co-transporter 2 inhibitors.","volume":"1","year":"2019","journal-title":"Am J Cardiol.."},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.","volume":"24","year":"2022","journal-title":"Eur J Heart Fail."},{"issue":"9","key":"ref20","first-page":"728","article-title":"Comparing adherence and persistence across 6 chronic medication classes.","volume":"15","year":"2009","journal-title":"J Manage Care Pharm."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2023\/00000038\/00000007\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T14:27:52Z","timestamp":1688480872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2023.288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"alternative-id":["2639-9636(20230701)38:7L.288;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2023.288","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}